Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rhopressa's Effects on Retinal Ganglion Cells in Glaucoma Patients
NCT07847073Phase 4Recruiting
- Start
- Oct 2026
- Primary completion
- Jan 2028
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of netarsudil in open-angle glaucoma (OAG) (2 arms). Primary endpoint: Change in Ganglion Cell Soma Density at 12 months. Started Oct 2026; status: recruiting.
02
Drugs
netarsudil
03
Conditions
open-angle glaucoma (OAG)
Beyond the preview
Go deeper on NCT07847073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07847073.